# KLOW Peptide Research — Angiogenesis, Matrix Remodeling, Anti-Inflammation and Cytoskeletal Literature | KLOW Terminal > Published research on KLOW peptide components: BPC-157 VEGFR2 angiogenesis, TB-500 wound re-epithelialization, GHK-Cu gene modulation, and KPV NF-κB suppression — each cited to source. KLOW peptide literature digest. Angiogenesis-vascular arm first. Matrix and skin arm second. Anti-inflammatory arm third. Cytoskeletal arm fourth. BLEND = null. ## TL;DR — the research record KLOW peptide has four parts. Each part has its own research history. None of the four is FDA-approved. The four together have never been studied. This page walks through the published findings for each component — what species, what dose, what outcome, what the citation is. KLOW is not a weight-loss compound and contains no GLP-1 or incretin-class agent. It is a tissue-repair and anti-inflammatory research blend, read here one process at a time. ## Angiogenesis-vascular arm: BPC-157 and TB-500 This is the dealt lens for this site. The angiogenesis-vascular findings from BPC-157 and the thymosin beta-4 / TB-500 literature are the primary focus. **BPC-157 and the VEGFR2 axis.** BPC-157 activates VEGFR2 (vascular endothelial growth factor receptor 2 — the cell-surface receptor that initiates angiogenic signaling) with downstream phosphorylation of PI3K, Akt, and eNOS (endothelial nitric oxide synthase — the enzyme that produces the signaling molecule nitric oxide in blood-vessel walls). This cascade promotes new blood-vessel formation and endothelial function in rodent models [1]. A 2025 review in Pharmaceuticals centered angiogenesis and nitric-oxide modulation as the unifying mechanisms of BPC-157 activity across injury models, noting the compound's ability to modulate the NO system in a manner partly resistant to L-NAME (a standard NO-synthesis blocker), suggesting an NO route distinct from classical NOS pathways [8]. BPC-157 also modulates vasomotor tone via the Src-Caveolin-1-eNOS pathway, providing a second vascular/endothelial mechanism beyond VEGFR2 [2]. **TB-500 / thymosin beta-4 and VEGF upregulation.** TB-500 is a synthetic fragment of the 43-amino-acid native protein thymosin beta-4 (Tβ4). Most of the foundational vascular data are for the full-length native protein. In a key in-vitro study, Tβ4 induced expression of VEGF (vascular endothelial growth factor — the protein that directly stimulates blood-vessel growth) in a hypoxia-inducible factor (HIF-1α)-dependent manner, providing a molecular route to the pro-angiogenic effects [4]. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization (the regrowth of surface tissue over a wound) by 42% at 4 days and up to 61% at 7 days versus saline controls, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis. As little as 10 pg of Tβ4 stimulated keratinocyte (skin cell) migration 2-3-fold in culture [3]. A 2007 mouse cardiac study showed that Tβ4 induced adult epicardial progenitor mobilization and neovascularization of ischemic myocardium, reactivating an embryonic developmental program [12]. A 2007 review described Tβ4's angiogenic modes of action — endothelial migration, tube formation — and therapeutic potential [13]. A 2024 immunology review documented that Tβ4 effects in tissue repair and inflammation are mediated via specialized pro-resolving lipid mediators — molecules that help resolve rather than simply suppress inflammation [14]. A 2024 study showed that Tβ4 improved the survival of cutaneous flaps (tissue transferred in surgery) in rats and activated the Wnt/β-catenin developmental signaling pathway [15]. **BLEND = null.** No controlled study has tested BPC-157 and TB-500 together, let alone all four KLOW components. Every angiogenic 'synergy' claim for KLOW is an extrapolation from the individual angiogenic mechanisms of BPC-157 and thymosin beta-4. ## Matrix and skin arm: GHK-Cu GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II), Copper Tripeptide-1, CAS 89030-95-5) is the mass-dominant component at approximately 62.5% by mass of the canonical 80 mg vial. It was first isolated from human plasma by Loren Pickart in 1973. Plasma GHK concentrations decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [5]. **Gene-expression modulation.** In bioinformatic analysis using the Connectivity Map database, GHK altered expression of approximately 31.2% of human genes at a 50%-or-greater threshold — increasing 59% of affected genes and suppressing 41%, with the strongest signals in the ubiquitin-proteasome system (protein quality control), DNA repair, antioxidant defense, and extracellular-matrix remodeling gene sets [7]. This is a published observation; the clinical significance of the breadth of this transcriptomic signature is not established. **Collagen and matrix synthesis.** GHK-Cu stimulates synthesis of collagen (structural protein in connective tissue), dermatan sulfate, chondroitin sulfate, and decorin (a proteoglycan that organizes collagen fibers). In a review of topical clinical studies, GHK-Cu increased collagen production in 70% of treated participants versus 50% for vitamin C and 40% for retinoic acid [5]. GHK-Cu supplies copper for lysyl oxidase (a copper-dependent enzyme that crosslinks collagen and elastin to give tissues their tensile strength). **Behavioral modulation in rodents.** The tripeptide Gly-His-Lys (without copper) reduced pain-induced aggressive-defensive behavior in rats, lowering attack frequency in a behavioral model [16]. This is an animal study; no human behavioral data exists for GHK or GHK-Cu. ## Anti-inflammatory arm: KPV KPV (Lys-Pro-Val, the C-terminal tripeptide fragment of alpha-MSH, CAS 67727-97-3, MW 342.44 Da) is the anti-inflammatory component of the KLOW blend at 10 of 80 mg. **PepT1-mediated uptake and NF-κB suppression.** KPV is a substrate of PepT1 (SLC15A1), a di/tripeptide transporter expressed in cells lining the intestine and upregulated in inflammatory conditions, with a Km of approximately 160 μM. In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV inhibited NF-κB p65 nuclear import (the switch that turns on inflammatory gene programs) and MAP-kinase ERK/p38 activation, reducing secretion of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8) [6]. In C57BL/6 mice, oral KPV delivered in drinking water reduced the severity of both DSS-induced and TNBS-induced colitis models — two standard preclinical models of intestinal inflammation [6]. These are mouse models with significant differences from human inflammatory bowel disease. Human data for KPV are limited to delivery mechanism studies and an IBD drug-development lineage that has not reached approval. ## Cytoskeletal arm: BPC-157 tendon data BPC-157 accelerated healing of a fully transected rat Achilles tendon (a complete cut-through, not a partial tear) across biomechanical testing, functional assessment, microscopic histology, and macroscopic inspection. BPC-157 also stimulated tendocyte outgrowth in cell culture. Doses of 10 μg, 10 ng, and 10 pg per rat were tested via intraperitoneal injection and locally; all showed accelerated recovery versus untreated controls [9]. This is a rodent tendon model. The TB-500 fragment's cytoskeletal contribution is the G-actin sequestration function of the LKKTET motif — binding monomeric actin to regulate its availability for the cytoskeletal assembly that drives cell migration. The integrin-linked kinase activation and epicardial progenitor mobilization reported for full-length thymosin beta-4 have not been demonstrated for the short TB-500 fragment. **First human safety pilot (BPC-157).** Intravenous BPC-157 at doses of 10 mg on day 1 and 20 mg on day 2 (in 250 cc saline as a 1-hour infusion) was administered to two healthy adults (a 58-year-old male and a 68-year-old female). No adverse events were observed and no measurable changes were detected in cardiac, hepatic, renal, thyroid, or glucose biomarkers [17]. The sample size is two. This is a safety observation, not an efficacy trial. ## Blend safety context: the Sports Medicine perspective A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal conditions — listing both TB-500/thymosin beta-4 and BPC-157 by name — concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [11]. The review did not test the KLOW combination. --- A phosphor-lit research console that queries the four-peptide KLOW literature one process at a time — each finding logged to its study, the absent blend-trial rendered as an explicit null, no clinic behind the terminal.